BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24582852)

  • 1. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives.
    Fleuren ED; Versleijen-Jonkers YM; Boerman OC; van der Graaf WT
    Biochim Biophys Acta; 2014 Apr; 1845(2):266-76. PubMed ID: 24582852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).
    Anderson P; Kopp L; Anderson N; Cornelius K; Herzog C; Hughes D; Huh W
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1703-15. PubMed ID: 18922107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
    Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
    Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.
    Fleuren EDG; Vlenterie M; van der Graaf WTA
    Front Oncol; 2023; 13():1013359. PubMed ID: 36994209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
    Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
    Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
    Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
    Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
    Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of TKI for Metastatic Osteogenic Sarcoma.
    Duffaud F
    Curr Treat Options Oncol; 2020 Jun; 21(8):65. PubMed ID: 32601895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
    Just MA; Van Mater D; Wagner LM
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29084. PubMed ID: 33894051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells.
    Li Y; Tanaka K; Li X; Okada T; Nakamura T; Takasaki M; Yamamoto S; Oda Y; Tsuneyoshi M; Iwamoto Y
    Int J Cancer; 2007 Sep; 121(6):1212-8. PubMed ID: 17520676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
    Olmos D; Tan DS; Jones RL; Judson IR
    Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
    Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Treatment of Pediatric Bone Sarcomas.
    Grohar PJ; Janeway KA; Mase LD; Schiffman JD
    Am Soc Clin Oncol Educ Book; 2017; 37():725-735. PubMed ID: 28561686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
    Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
    Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition.
    Soni UK; Wang Y; Pandey RN; Roberts R; Pressey JG; Hegde RS
    Clin Cancer Res; 2023 Jan; 29(2):458-471. PubMed ID: 36394520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib as an emerging treatment for sarcoma.
    Schöffski P; Blay JY; Ray-Coquard I
    Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.